Oxford Biomedica (OXB) announced on June 23, 2025, that it has completed the acquisition of the remaining 10% stake in its U.S. subsidiary from Q32 Bio Inc., bringing OXB's ownership to 100%. This transaction aligns with OXB's global strategy and supports its long-term growth in the viral vector manufacturing market.
As previously disclosed in OXB's Preliminary Results on April 9, OXB US exercised its call option on March 1 to acquire the final 10% interest from Q32 Bio. The stake was originally held by Homology Medicines, which merged with Q32 Bio in 2024. The transfer of Q32 Bio's holding means OXB US is now wholly owned by OXB.
For Q32 Bio, this represents a divestiture of a non-core asset, further streamlining its focus on its lead therapeutic programs. The financial terms of the transaction for Q32 Bio were not explicitly detailed in the provided content, beyond the fact that OXB US exercised a call option, but it supports the company's strategic pivot.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.